An Amince da Daraxonrasib don Ciwon Daji na Pancreatic

An amince da Daraxonrasib (Rasonque by Revolution Medicines, Inc.), wani maganin hana ciwon daji na iyali na RAS GTPase don maganin manya da ke fama da ciwon daji na pancreas (mPDAC) a ranar 26 ga Agusta 2026 daga Hukumar Abinci da Magunguna ta Amurka (FDA). Ciwon daji na pancreas shine nau'in ciwon daji na pancreas da aka fi sani. Amincewa da daraxonrasib yana ba wa waɗannan marasa lafiya sabon zaɓi na magani. An amince da maganin Tumour Treating Fields (TTFields) ta hanyar amfani da filayen lantarki daban-daban a baya don ciwon daji na pancreas da ya ci gaba a yankin a ranar 12 ga Fabrairu 2026.

Amincewar da aka yi wa daraxonrasib ta dogara ne akan sakamakon da aka samu daga wani gwaji na asibiti na mataki na 3 wanda ya shafi manya 500 da suka kamu da cutar sankarar pancreas da aka yi wa magani a baya, kuma an gano cewa daraxonrasib yana inganta matsakaicin rayuwa zuwa watanni 13.2 idan aka kwatanta da watanni 6.7 don maganin chemotherapy na yau da kullun. 

Sinadarin RAS shine babban abin da ke haifar da ci gaban ciwon daji a yawancin marasa lafiya da ke fama da ciwon daji na pancreas. Daraxonrasib yana nufin wannan. Shawarar da aka ba da shawarar ita ce 300 MG a baki sau ɗaya a rana har sai cutar ta ci gaba ko kuma gubar da ba za a iya yarda da ita ba, kuma an amince da ita don maganin manya da ke fama da ciwon daji na pancreas waɗanda suka sami aƙalla magani ɗaya a baya ko kuma ba su da 'yancin yin maganin da ya shafi tsarin da yawa.

Ciwon daji na pancreas adenocarcinoma shine kusan kashi 3.2% na dukkan cututtukan da suka shafi kansa, duk da haka wannan shine babban kaso na mace-macen da ake samu sakamakon gano cutar kansa a makare, rashin lafiyar da ta shafi cututtuka masu tsanani, da kuma ƙarancin zaɓuɓɓukan magani. Maganin da ake bayarwa a yanzu yana ba da fa'ida kaɗan ga marasa lafiya da aka yi wa magani a baya na ciwon daji na pancreas adenocarcinoma (mPDAC). Ga irin waɗannan marasa lafiya, maganin da aka yi da daraxonrasib ya haifar da tsawon rai gaba ɗaya da rayuwa ba tare da ci gaba ba fiye da chemotherapy. 

Ga ciwon daji na pancreas da ya ci gaba a yankin, FDA ta amince da maganin Tumour Treating Fields (TTFields) ta hanyar amfani da wutar lantarki a madadin filayen lantarki a farkon ranar 12 ga Fabrairu, 2026. Wannan ya kasance mai mahimmanci ganin cewa kula da ciwon daji na pancreas yana da ƙalubale saboda rashin kyakkyawan hasashen da kuma ƙarancin rayuwa.

***

References: 

1. Sanarwar FDA News. FDA Ta Amince Da Maganin Da Aka Yi Niyya Na Farko Don Ciwon Daji Mai Yaɗuwa. 26 ga Agusta 2026. Akwai a https://www.fda.gov/news-events/press-announcements/fda-approves-first-class-targeted-therapy-metastatic-pancreatic-cancer
2. Hukumar Abinci da Magunguna ta Amurka (FDA) ta amince da maganin daraxonrasib don maganin ciwon daji na pancreas. Akwai a https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daraxonrasib-metastatic-pancreatic-adenocarcinoma
3. O'Reilly EM, et al 2026. Daraxonrasib ko Chemotherapy a cikin Ciwon daji na Pancreatic da aka yi wa magani a baya. NEJM. 31 Mayu 2026. DOI: https://doi.org/10.1056/NEJMoa2605555
4. Nazarin Mataki na 3 na Daraxonrasib (RMC-6236) a cikin Marasa Lafiya da suka Yi Maganin Ciwon Dubuwar Pancreatic (PDAC) a Baya (RASolute 302). https://clinicaltrials.gov/study/NCT06625320
5. Sanarwar Labarai ta FDA - FDA ta Amince da Na'urar Farko don Maganin Ciwon Pancreatic. An buga a ranar 12 ga Fabrairu, 2026. Akwai a https://www.fda.gov/news-events/press-announcements/fda-approves-first-its-kind-device-treat-pancreatic-cancer  

***

Shafukan da suka shafi: 

1. An amince da filayen maganin ciwon daji (TTFields) don magance ciwon daji na pancreas (13 Fabrairu 2026)

***